News

Filter by:

Showing 12 of 559 Results

November 30, 2023 General News

Acadia Pharmaceuticals Initiates Pivotal Phase 3 Study of Carbetocin (ACP-101) for the Treatment of Hyperphagia in Prader-Willi Syndrome

November 27, 2023 General News

Acadia Pharmaceuticals Initiates Phase 2 Clinical Trial of ACP-204 for the Treatment of Alzheimer’s Disease Psychosis

November 21, 2023 General News

Acadia Pharmaceuticals Announces Change in Research and Development Leadership

November 14, 2023 General News

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

November 2, 2023 Earnings News

Acadia Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operating Overview

October 31, 2023 General News

Acadia Pharmaceuticals to Participate in the Guggenheim Securities 5th Annual Inflammation & Immunology Conference

October 23, 2023 General News

Acadia Pharmaceuticals Announces the Rett Sibling Scholarship Program

October 19, 2023 General News

Acadia Pharmaceuticals to Announce Third Quarter Financial Results on November 2, 2023

October 18, 2023 General News

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 22, 2023 General News

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 19, 2023 General News

Acadia Pharmaceuticals Appoints Albert Kildani as Senior Vice President, Investor Relations and Corporate Communications

September 18, 2023 Company Statement

Acadia Pharmaceuticals Announces Label Update for NUPLAZID® (pimavanserin)

Load More Results